Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-041)
CompletedPhase 3NCT00393354
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Study the effect of etoricoxib 60 mg and 90 mg compared to placebo to treat chronic low back pain.
Study details
- Official title
- A Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Trial to Assess the Efficacy and Safety of MK0663 in Patients With Chronic Low Back Pain
- Conditions
- Recurrent Low Back Pain
- Interventions
- Drug: MK0663, Etoricoxib / Duration of Treatment : 12 Weeks
- Drug: Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks
- Sponsor
- Organon and Co
- Start date
- 2000-04
- Primary completion
- 2000-11
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Low back pain for previous 3 months and majority of days in last month * Regular use of acetaminophen or NSAID to treat low back pain in past month * Judged to be in otherwise good health Exclusion Criteria: * Low back pain that is due to secondary causes * Radicular/myelopathic pain * Surgery for low back pain within the past 6 months * Active lawsuit or claim pertaining to their low back pain * Disease that may confound the results of the study or pose risk to the patients * Corticosteroid use in past month * Previous participation in MK0663 study
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00393354